Atypical presentation of macrophagic myofasciitis 10 years post vaccination

Neuromuscular Disorders

Volumn 16, Issue 12, 2006, Pages 867-869

  Ryan, Aisling M ^a   Bermingham, Niamh ^a   Harrington, Hugh J ^b   Keohane, Catherine ^a  

^a Department of Medicine National University of Ireland Cork   (Ireland)

^b MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Macrophagic myofasciits; Myalgia; Vaccination

Indexed keywords

CORTICOSTEROID; HEPATITIS VACCINE; MENINGOCOCCUS VACCINE; TETANUS TOXOID; YELLOW FEVER VACCINE;

ADULT; ARM; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; HEPATITIS A; HUMAN; HUMAN TISSUE; IRELAND; LOW DRUG DOSE; MACROPHAGIC MYOFASCIITIS; MENINGOCOCCOSIS; MYOSITIS; PRIORITY JOURNAL; TETANUS; THORAX; VACCINATION; YELLOW FEVER;

ALUMINUM HYDROXIDE; ANTI-INFLAMMATORY AGENTS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNE SYSTEM; IMMUNE SYSTEM DISEASES; MACROPHAGE ACTIVATION; MIDDLE AGED; MUSCLE, SKELETAL; MYOSITIS; STEROIDS; TIME; TIME FACTORS; VACCINATION;

EID: 33845211930     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2006.07.017     Document Type: Article

References (10)

1. Gherardi R.K., Coquet M., Cherin P., et al. Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Francaise contre les Myopathies (AFM). Lancet 352 (1998) 347-352
2. Gherardi R.K., Coquet M., Cherin P., et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 124 (2001) 1821-1831
3. Gherardi R.K., and Authier F.J. Aluminum inclusion macrophagic myofasciitis: a recently identified condition. Immunol Allergy Clin North Am 23 (2003) 699-712
4. Di Muzio A., Capasso M., Verrotti A., et al. Macrophagic myofasciitis: an infantile Italian case. Neuromuscul Disord 14 (2004) 175-177
5. Shingde M, Hughes J, Boadle R, Wills EJ, Pamphlett R. Macrophagic myofasciitis associated with vaccine-derived aluminium. Med J Aust 2005;1(183):145-146.
6. World Health Organisation Vaccine Safety Advisory C. Macrophagic myofasciitis and aluminium-containing vaccines. Wkly Epidemiol Rec 74 (1999) 338-340
7. Guis S., Pellissier J.F., Nicoli F., et al. HLA-DRB1*01 and macrophagic myofasciitis. Arthritis Rheum 46 (2002) 2535-2537
8. Authier F.J., Cherin P., Creange A., et al. Central nervous system disease in patients with macrophagic myofasciitis. Brain 124 (2001) 974-983
9. Cherin P., Authier F.J., Gherardi R.K., et al. Gallium-67 scintigraphy in macrophagic myofasciitis. Arthritis Rheum 43 (2000) 1520-1526
10. Guis S., Mattei J.P., Pellissier J.F., et al. MRI and 31PMR spectroscopy investigations of muscle function disclose no abnormality in macrophagic myofasciitis. J Rheumatol 31 (2004) 2313-2314